Targeting LSD1 and FOXA1 in prostate cancer

FOXA1 is a key pioneer factor in androgen-receptor activity but has been an elusive drug target. A new study shows that inhibition of the associated cofactor LSD1 modifies the methylation state of FOXA1, thus resulting in chromatin dissociation and tumor inhibition, even in models of treatment-resis...

Full description

Saved in:
Bibliographic Details
Published inNature genetics Vol. 52; no. 10; pp. 1002 - 1003
Main Authors Omarjee, Soleilmane, Carroll, Jason S.
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.10.2020
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:FOXA1 is a key pioneer factor in androgen-receptor activity but has been an elusive drug target. A new study shows that inhibition of the associated cofactor LSD1 modifies the methylation state of FOXA1, thus resulting in chromatin dissociation and tumor inhibition, even in models of treatment-resistant prostate cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
ISSN:1061-4036
1546-1718
DOI:10.1038/s41588-020-0702-6